Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
The Lancet. Child & Adolescent Health|July 21, 2019
Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling studyKendra K Radtke, Kelly E Dooley, Peter J Dodd, et al.American Journal of Respiratory and Critical Care Medicine|May 16, 2020
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis InfectionJennifer E Hibma, Kendra K Radtke, Susan E Dorman, et al.Antimicrobial Agents and Chemotherapy|October 4, 2021
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling StudyKendra K Radtke, Jacqueline P Ernest, Nan Zhang, et al.Expert Review of Respiratory Medicine|February 17, 2022
Tuberculosis in children with severe acute malnutritionBryan J Vonasek, Kendra K Radtke, Paula Vaz, et al.Journal of Clinical Pharmacology|July 6, 2023
Predicted Pharmacokinetic Interactions Between Hormonal Contraception and Single or Intermittently Dosed RifampicinKendra K Radtke, Jeremy Hill, Anne Schoenmakers, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 16, 2018
Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort StudyKendra K Radtke, Peter Bacchetti, Kathryn Anastos, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 22, 2018
Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected WomenLeah H Rubin, Kendra K Radtke, Seenae Eum, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2022
Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant TuberculosisJennifer A Hughes, Belén P Solans, Heather R Draper, et al.Antimicrobial Agents and Chemotherapy|June 26, 2023
QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric StudiesAli Mohamed Ali, Kendra K Radtke, Anneke C Hesseling, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2021
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in ChildrenKendra K Radtke, Anneke C Hesseling, J L Winckler, et al.Pageof 4